After the company reported mixed first-quarter financial results that were better than expected on the top line and worse than expected on the bottom line, shares in Antares Pharma (NASDAQ: ATRS) had tumbled 12.3% at 12 p.m. EST on Tuesday.
The healthcare company delivered robust revenue growth in Q1 because of Xyosted, a long-lasting testosterone drug, and Teva Pharmaceutical Industries' (NYSE: TEVA) generic version of Mylan's EpiPen, which uses Antares technology. Sales were $33.1 million, eclipsing industry watchers' estimates by $2.56 million and up 42.1% from the same quarter last year.
Image source: Getty Images.